Journal
HUMAN IMMUNOLOGY
Volume 71, Issue 9, Pages 888-891Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2010.05.023
Keywords
CTLA4; Polymorphism; Hepatocellular carcinoma; Cervical cancer
Categories
Funding
- Program for Changjiang Scholars and Innovative Research Team in University [IRT0631]
- National Natural Science Foundation of China [30800946]
- Jiangsu 333 program [DG216D5023]
- Natural Science Foundation of Jiangsu Colleges [08KJB330002]
Ask authors/readers for more resources
Accumulated evidence suggested that cytotoxic T-lymphocyte antigen 4 (CTLA4) plays an important role in the negative regulation of T-cell proliferation and activation, and thus participates in antitumor immunity and cancer surveillance. Previously we reported that the CTLA4 49A/G (rs231775) single nucleotide polymorphism (SNP) was a candidate cancer susceptibility marker for breast, lung, esophageal, and gastric cancers. In the present study, we expanded our study to two infection-related cancers, namely, hepatocellular carcinoma (HCC) and cervical cancer. We genotyped rs231775 in two independent case-control studies of 864 HCC patients and 864 control subjects, and 719 cervical cancer patients and 719 control subjects. In the multivariate logistic regression models, CTL44 +49 A/G variant genotype was associated with increased risk (AA vs GG) by 1.43-fold (95% CI = 0.94-2.17) for HCC, and 1.66-fold (95% CI = 1.13-2.44) for cervical cancer. Taken together, the results suggest that CTLA4 rs231775 may serve as a common cancer susceptibility marker. (C) 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available